본문바로가기
Q
U
I
C
K

Global Innovative Partner of Vaccine and Biotech SK bioscience

From Prevention To Cure
mouse scroll icon SCROLL DOWN

What’s New

  • SK bioscience News SK bioscience Submits Emergency Use...

    Company submitted an application for CMA of SKYCovione™ to MHRA and EMA, followed by EUL to WHO. ...

    More
  • News SK bioscience Begins First Shi...

    ·   609,000 doses of advance purchased SKYCovione...

    More
  • News SK-Bill & Melinda Gates Founda...

      [16 August 2022] SK bioscience announced that T...

    More
  • News SK bioscience Announces Adoles...

    SK extends the vaccination age of Nuvaxovid to 12 ...

    More
  • News SK bioscience Submits Applicat...

     SK bioscience will accelerate to apply for emerg...

    More

Investor Relations

0 PRESENT PRICE (WON)

0WON

0.00%

Our Products

  • SKYCovione Multi Inj.
  • SKY Cellflu prefilled syringe
  • SKY Cellflu Quadrivalent prefilled syringe
  • SKY Zoster Inj.
  • SKY Varicella Inj.




PRODUCTS SKYCovione Multi Inj.

South Korea’s first developed COVID-19 vaccine, SKYCovione™ is a recombinant protein-based vaccine, which has long been evaluated to have efficacy and safety.
SKYCovione™ can be refrigerated at 2–8 degrees Celsius for transport and can be stored for a longer period.
We expect long-term demand to rise because SKYCovione™ can play a key role in increasing vaccination rates in underdeveloped countries where the imbalance in vaccine supply and demand continues.

SKYCovione Multi Inj. image